AXONIS Therapeutics

AXONIS Therapeutics is developing first-in-class therapies that enable neurons to resist degeneration, restore excitation/inhibition balance and regenerate, in order to rescue nervous system functions. Their lead drug candidate, an oral KCC2 (CNS-specific chloride transporter) enhancer, acts as a multi-modal neuromodulatory therapy for spinal cord injury, neuropathic pain and other neurological disorders.